{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.0","upperLimit":"331.0","value":"196.0"},{"comment":"Upper limit of CI was not estimable due to censoring.","groupId":"OG001","lowerLimit":"98.0","upperLimit":"NA","value":"451.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Overall number of participants analyzed are the number of participants with events.","reportingStatus":"POSTED","timeFrame":"Up to 52 months","title":"Time to Resolution of Peripheral Neuropathy (PN) Events","type":"SECONDARY","unitOfMeasure":"days"}